Table 2.
Laboratory test baseline of liver enzymes and other risk factors of participants (mean ± SD).
| Variables | Total | Metabolic syndrome | Hypertension | CVD | |||
|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | ||
| ALT (IU/l) | 24.9 ± 14.6 | 27.6 ± 27.1 | 23.5 ± 13.9∗∗ | 24.4 ± 13 | 25 ± 14.9 | 24.1 ± 13.2 | 25 ± 14.9∗ |
| AST (IU/l) | 21.4 ± 8.8 | 21.8 ± 8.5 | 21.2 ± 8.9∗∗ | 21.3 ± 8.1 | 21.4 ± 8.9 | 21.2 ± 8.3 | 21.4 ± 8.9 |
| ALT/AST ratio | 1.1 ± 0.36 | 1.2 ± 0.37 | 1.0 ± 0.34∗∗ | 1.1 ± 0.34 | 1.1 ± 0.36 | 1.1 ± 0.34 | 1.1 ± 0.36 |
| GGT (IU/l) | 24.6 ± 19.9 | 28.9 ± 22.2 | 22.4 ± 18.2∗∗ | 26.8 ± 20.1 | 24.2 ± 19.6∗∗ | 26.6 ± 20 | 24.2 ± 19.8∗∗ |
| ALP (IU/l) | 197.9 ± 63.4 | 209.6 ± 73.6 | 191.7 ± 56.3∗∗ | 214.3 ± 89.7 | 194.8 ± 56.7∗∗ | 211 ± 86.7 | 195.2 ± 57.2∗∗ |
| Chol (mg/dl) | 185.4 ± 38 | 191.9 ± 38.8 | 181.7 ± 36.9∗∗ | 191.6 ± 40.3 | 184 ± 37.3∗∗ | 187.4 ± 40.4 | 184.7 ± 37.3∗ |
| TG (mg/dl) | 137.3 ± 81.7 | 198.2 ± 97.1 | 105.9 ± 48.7∗∗ | 153.9 ± 91.3 | 134.2 ± 79.4∗∗ | 149.7 ± 86.8 | 134.8 ± 80.5∗∗ |
| LDL (mg/dl) | 102 ± 25.4 | 106.2 ± 26.2 | 99.8 ± 24.9∗∗ | 105.7 ± 26.8 | 101.2 ± 25.1∗∗ | 103.2 ± 26.7 | 101.7 ± 25.1∗ |
| HDL (mg/dl) | 46.2 ± 11.3 | 40 ± 8.6 | 49.4 ± 11.1∗∗ | 46.1 ± 11 | 46.2 ± 11.3 | 46.1 ± 11.2 | 46.2 ± 11.3 |
| FBS (mg/dl) | 96.9 ± 29.7 | 109.2 ± 39.7 | 90.6 ± 20.2∗∗ | 106.8 ± 39.6 | 95.1 ± 27.2∗∗ | 107.7 ± 39.9 | 94.8 ± 26.7∗∗ |
ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; ALP: alkaline phosphatase; Chol: cholesterol; TG: triglyceride; LDL: low-density lipoprotein; HDL: high-density lipoprotein; FBS: fast blood glucose. ∗p value < 0.05. ∗∗p value < 0.001.